Levetiracetam formulations

Specific myoclonic syndromes are usually treated with valproate an intravenous formulation can be used acutely if needed. It is nonsedating and can be dramatically effective. Other patients respond to clonazepam, nitrazepam, or other benzodiazepines, although high doses may be necessary, with accompanying drowsiness. Zonisamide and levetiracetam may be useful. Another specific myoclonic syndrome, juvenile myoclonic epilepsy, can be aggravated by phenytoin or carbamazepine valproate is the drug of choice followed by lamotrigine and topiramate. 

In a study, 10 healthy subjects were given a 500-mg levetiracetam tablet with 120 mL of water or crushed and mixed with either 4 oz apple sauce or 120 mL of an enteral nutrition formulation Sustacal). The overall rate and extent of absorption of oral levetiracetam were not significantly affected by crushing and mixing the tablet with either apple sauce or an enteral nutrition preparation, although the peak serum level of levetiracetam may be slightly reduced if it is mixed with enteral nutrition. ... 

The use, safety, and efficacy of levetiracetam in 51 patients in intensive care unit have been retrospectively analysed [179 ]. Nineteen patients first received levetiracetam intravenously formulation before receiving it orally, 18 received the... 

Drug formulations Extended-release levetiracetam Once-daily extended-release levetiracetam as add-on therapy in relractory partial-onset seizures has been evaluated in a 12 week, double-blind, randomized, placebo-controlled trial in 158 patients [204. There were adverse events in 41 (53%) of those who used extended-release leve-tira-cetam and in 43 (54%) of those who used placebo the most common were somnolence, influenza, irritability, nasopharyngitis, dizziness, and nausea. 

Drug formulations The safety and efficacy of extended-release levetiracetam was evaluated in a randomized double-blind study at a dose of either 1000 mg/day or 2000 mg/day the most common adverse events were somnolence (21.9%), headache (19.7%), and convulsion (14.9%) [108 ]. Similar adverse effects have been reported with immediate release formulation of levetiracetam. 

---

See also in sourсe #XX -- [ ]

---